Skip to main content

Advertisement

SpringerLink
Log in

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab

Evidence for disease heterogeneity

  • LETTER TO THE EDITORS
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913–919

    Article  PubMed  CAS  Google Scholar 

  2. Lassmann H, Brück W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218

    Article  PubMed  Google Scholar 

  3. Kieseier BC, Wiendl H, Hemmer B, Hartung HP (2007) Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 20:286–293

    Article  PubMed  CAS  Google Scholar 

  4. Polman C, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910

    Article  PubMed  CAS  Google Scholar 

  5. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923

    Article  PubMed  CAS  Google Scholar 

  6. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62:258–264

    Article  PubMed  Google Scholar 

  7. Stüve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer BH, Kieseier BC (2005) Clinical stabilization and effective B cell depletion in the cerebrospinal fluid and peripheral blood in a patient with fulminant relapsing remitting multiple sclerosis. Arch Neurol 62:1620–1623

    Article  PubMed  Google Scholar 

  8. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180:63–70

    Article  PubMed  CAS  Google Scholar 

  9. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH for the HERMES Trial Group (2008) B-cell depletion with an anti-CD20 monoclonal antibody (rituximab) reduces disease activity in relapsing remitting multiple sclerosis: results of a placebocontrolled randomized phase II trial. N Engl J Med 358:676–688

    Article  PubMed  CAS  Google Scholar 

  10. McFarland HF (2008) The B cell – old player, new position on the team. N Engl J Med 358:664–665

    Article  PubMed  CAS  Google Scholar 

  11. Keegan M, König F, McClelland R, Brück W, Morales Y, Bitsch A, Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, Lucchinetti CF (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579–582

    Article  PubMed  Google Scholar 

  12. Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand‘Maison F, Hemmer B, Monson NL, Racke MK (2006) Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 63:1383–1387

    Article  PubMed  Google Scholar 

  13. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand‘Maison F, Bar-Or A (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59:748–754

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, Heinrich-Heine University, Moorenstrasse 5, 40225, Düsseldorf, Germany

    V. I. Leussink, H. C. Lehmann, G. Meyer zu Hörste, H.-P. Hartung, O. Stüve &  B. C. Kieseier

  2. Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas, USA

    O. Stüve

  3. Dept. of Neurology and Dept. of Immunology, University of Texas Southwestern Medical, Center at Dallas, Dallas, Texas, USA

    O. Stüve

Authors
  1. V. I. Leussink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. C. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Meyer zu Hörste
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-P. Hartung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Stüve
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. C. Kieseier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. C. Kieseier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leussink, V.I., Lehmann, H.C., Meyer zu Hörste, G. et al. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. J Neurol 255, 1436–1438 (2008). https://doi.org/10.1007/s00415-008-0956-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-0956-x

Keywords

Search

Navigation